ArticleFrontiers in oncology2022

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer.

Liang Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.